| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | RAB6KIFL/KIF20A表位肽及包含它的疫苗 | CN201410198295.8 | 2009-10-15 | CN104086625A | 2014-10-08 | 西村泰治; 今井克宪; 中村佑辅; 角田卓也 |
| 本申请涉及RAB6KIFL/KIF20A表位肽及包含它的疫苗。本发明提供包含选自SEQ ID NO:3、4和5的氨基酸序列的寡肽。本发明还提供药物组合物，其包含选自SEQ ID NO:3、4和5的氨基酸序列，配制为用于治疗或预防受试者中的癌症。此外，本发明还提供使用这样的寡肽和药剂诱导免疫应答的方法。 | ||||||
| 2 | RAB6KIFL/KIF20A表位肽及包含它的疫苗 | CN200980151824.6 | 2009-10-15 | CN102264897B | 2014-06-11 | 西村泰治; 今井克宪; 中村佑辅; 角田卓也 |
| 本发明提供包含选自SEQ？ID？NO：3、4和5的氨基酸序列的寡肽。本发明还提供药物组合物，其包含选自SEQ？ID？NO：3、4和5的氨基酸序列，配制为用于治疗或预防受试者中的癌症。此外，本发明还提供使用这样的寡肽和药剂诱导免疫应答的方法。 | ||||||
| 3 | 腺癌、宫颈癌、胆管细胞癌、CML、结直肠癌、胃癌、MPHOSPH1肽及包含它们的疫苗 NSCLC、淋巴瘤、骨肉瘤、前列腺癌、肾癌和软组织 | CN201280039507.7 | 2012-08-09 | CN103732743B | 2017-03-15 | 角田卓也; 大泽龙司; 吉村祥子; 渡边朝久; 中村佑辅 |
| 肿瘤的治疗和/或预防。如本申请中更详细地讨论的，衍生自MPHOSPH1的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞(CTL)，因此适于在癌症免疫治疗，更具体地说是癌症疫苗的语境中使用。本发明的肽涵盖上述的MPHOSPH1衍生的氨基酸序列，以及其修饰形式，其中取代、缺失、插入或添加了一个、两个或几个氨基酸，只要这样的修饰形式保留所需的原始序列的CTL诱导能力。此外还提供编码任何上述肽的多核苷酸，以及包含任何上述肽或多核苷酸的药物作用剂或药物组合物。本发明的肽、多核苷酸、和药物作用剂或药物组合物特别有用于癌症和肿瘤，包括例如膀胱癌、乳 | ||||||
| 4 | RAB6KIFL/KIF20A表位肽及包含它的疫苗 | CN201410198295.8 | 2009-10-15 | CN104086625B | 2016-08-31 | 西村泰治; 今井克宪; 中村佑辅; 角田卓也 |
| 本申请涉及RAB6KIFL/KIF20A表位肽及包含它的疫苗。本发明提供包含选自SEQ ID NO:3、4和5的氨基酸序列的寡肽。本发明还提供药物组合物，其包含选自SEQ ID NO:3、4和5的氨基酸序列，配制为用于治疗或预防受试者中的癌症。此外，本发明还提供使用这样的寡肽和药剂诱导免疫应答的方法。 | ||||||
| 5 | MPHOSPH1肽及包含它们的疫苗 | CN201280039507.7 | 2012-08-09 | CN103732743A | 2014-04-16 | 角田卓也; 大泽龙司; 吉村祥子; 渡边朝久; 中村佑辅 |
| 如本申请中更详细地讨论的，衍生自MPHOSPH1的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞(CTL)，因此适于在癌症免疫治疗，更具体地说是癌症疫苗的语境中使用。本发明的肽涵盖上述的MPHOSPH1衍生的氨基酸序列，以及其修饰形式，其中取代、缺失、插入或添加了一个、两个或几个氨基酸，只要这样的修饰形式保留所需的原始序列的CTL诱导能力。此外还提供编码任何上述肽的多核苷酸，以及包含任何上述肽或多核苷酸的药物作用剂或药物组合物。本发明的肽、多核苷酸、和药物作用剂或药物组合物特别有用于癌症和肿瘤，包括例如膀胱癌、乳腺癌、宫颈癌、胆管细胞癌、CML、结直肠癌、胃癌、NSCLC、淋巴瘤、骨肉瘤、前列腺癌、肾癌和软组织肿瘤的治疗和/或预防。 | ||||||
| 6 | RAB6KIFL/KIF20A表位肽及包含它的疫苗 | CN200980151824.6 | 2009-10-15 | CN102264897A | 2011-11-30 | 西村泰治; 今井克宪; 中村佑辅; 角田卓也 |
| 本发明提供包含选自SEQ ID NO：3、4和5的氨基酸序列的寡肽。本发明还提供药物组合物，其包含选自SEQ ID NO：3、4和5的氨基酸序列，配制为用于治疗或预防受试者中的癌症。此外，本发明还提供使用这样的寡肽和药剂诱导免疫应答的方法。 | ||||||
| 7 | Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing | US15706849 | 2017-09-18 | US10087446B2 | 2018-10-02 | David Sharp |
| Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain. | ||||||
| 8 | MPHOSPH1 PEPTIDES AND VACCINES INCLUDING THE SAME | US14131019 | 2012-08-09 | US20140154281A1 | 2014-06-05 | Takuya Tsunoda; Ryuji Osawa; Sachiko Yoshimura; Tomohisa Watanabe; Yusuke Nakamura |
| As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor. | ||||||
| 9 | Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | US14707230 | 2015-05-08 | US10064924B2 | 2018-09-04 | Hans-Georg Rammensee; Stefan Stevanovic; Juliane Stickel; Daniel Kowalewski; Claudia Berlin |
| The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | ||||||
| 10 | Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing | US15023869 | 2014-09-12 | US09994845B2 | 2018-06-12 | David Sharp |
| Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain. | ||||||
| 11 | MPHOSPH1 peptides and vaccines including the same | US14131019 | 2012-08-09 | US09458447B2 | 2016-10-04 | Takuya Tsunoda; Ryuji Osawa; Sachiko Yoshimura; Tomohisa Watanabe; Yusuke Nakamura |
| As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor. | ||||||
| 12 | Method of preventing transport of a neurotropic virus and identifying agents for achieving same | US10031492 | 2000-07-20 | US06953661B1 | 2005-10-11 | Russell John Diefenbach; Monica Miranda-Saksena; Eve Margaret Diefenbach; David James Holland; Anthony Lawrence Cunningham; Mark Penfold; Patricia Joan Armati |
| A method of preventing transport of a Herpes simplex virus within a neuron, comprising preventing interaction between a structural tegument protein US11 of the virus and a motor protein, Kinesin in the neuron such that virus transport in the neuron is prevented. An antiviral composition is also provided, comprising a compound capable of preventing interaction between a structural tegument protein of a neurotropic virus and a neuron or cell. | ||||||
| 13 | ＲＡＢ６ＫＩＦＬ／ＫＩＦ２０Ａエピトープペプチドおよびそれを含むワクチン | JP2011517539 | 2009-10-15 | JP5663790B2 | 2015-02-04 | 西村 泰治; 泰治 西村; 克憲 今井; 中村 祐輔; 祐輔 中村; 卓也 角田 |
| 14 | ＭＰＨＯＳＰＨ１ペプチドおよびそれを含むワクチン | JP2014107878 | 2014-05-26 | JP2014209908A | 2014-11-13 | TSUNODA TAKUYA; OSAWA RYUJI; YOSHIMURA SACHIKO; WATANABE TOMOHISA; NAKAMURA YUSUKE |
| 【課題】がんワクチンとして有効な新規ペプチドの提供。【解決手段】M期リンタンパク質1(MPHOSPH1)由来の単離されたエピトープペプチドであり、HLA抗原に結合し、かつ細胞傷害性Tリンパ球(CTL)を誘導する。前記MPHOSPH1由来のアミノ酸配列、および、改変型が元の配列の必要なCTL誘導能を保持する限り、1個、2個、または数個のアミノ酸が置換、欠失、挿入または付加されているその改変型の両方を包含する。前記ペプチドのいずれかをコードするポリヌクレオチド。当該ペプチド、ポリヌクレオチドは、膀胱癌、乳癌、子宮頸癌、胆管細胞癌、CML、結腸直腸癌、胃癌、NSCLC、リンパ腫、骨肉腫、前立腺癌、腎癌および軟組織腫瘍を含むがんおよび腫瘍の治療および予防のいずれかまたは両方に使用する。【選択図】なし | ||||||
| 15 | 転移を阻害し、線維症を処置し、かつ創傷の治癒を向上させる方法および組成物 | JP2016519372 | 2014-09-12 | JP2016539084A | 2016-12-15 | シャープ、デーヴィッド |
| Kif19およびCep192に関する発見に基づいて転移を阻害または処置する方法および組成物が提供される。創傷の治癒を高め、線維症を処置し、瘢痕化を和らげ、かつ神経痛を処置する方法および組成物が提供される。 | ||||||
| 16 | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) | US16032231 | 2018-07-11 | US20180311330A1 | 2018-11-01 | Hans-Georg Rammensee; Stefan Stevanovic; Juliane Stickel; Daniel Johannes Kowalewski; Claudia Berlin |
| The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | ||||||
| 17 | METHODS AND COMPOSITIONS TO INHIBIT METASTASIS AND TO TREAT FIBROSIS AND TO ENHANCE WOUND HEALING | US15706849 | 2017-09-18 | US20180057816A1 | 2018-03-01 | David Sharp |
| Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain. | ||||||
| 18 | RAB6KIFL/KIF20A epitope peptide and vaccines containing the same | US14500877 | 2014-09-29 | US09132176B2 | 2015-09-15 | Yasuharu Nishimura; Katsunori Imai; Yusuke Nakamura; Takuya Tsunoda |
| The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents. | ||||||
| 19 | RAB6KIFL/KIF20A EPITOPE PEPTIDE AND VACCINES CONTAINING THE SAME | US14500877 | 2014-09-29 | US20150017193A1 | 2015-01-15 | Yasuharu NISHIMURA; Katsunori IMAI; Yusuke NAKAMURA; Takuya TSUNODA |
| The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents. | ||||||
| 20 | RAB6KIFL/KIF20A epitope peptide and vaccines containing the same | US13125548 | 2009-10-15 | US08883966B2 | 2014-11-11 | Yasuharu Nishimura; Katsunori Imai; Yusuke Nakamura; Takuya Tsunoda |
| The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents. | ||||||
QQ群二维码
意见反馈
意见反馈